Health:
In clinical studies over the past 20 years, our licensed Immunitor oral pill immunotherapeutics have consistently proven the science and demonstrated superior safety and efficacy in diseases such as late-stage cancers, tuberculosis, HIV/AIDS, hepatitis.In many cases where other treatments have failed.
Key Capital is now working with Immunitor towards product registrations and commercializations that will contribute to a better healthcare future.
NEW YORK, NY, April 8, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that in association with its partner, global oral pill vaccine pioneer Immunitor (Thailand) Co., Ltd, the Company is today launching its unique M.vaccae and magnesium dietary supplement in the $18 billion Anxiety and Stress market.
NEW YORK, NY, April 7, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises the Company is launching https://MaxCellLife.com today specializing in the sales and marketing of science driven supplement and skincare products.
NEW YORK, NY, March 12, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that in association with its partner, global oral pill vaccine pioneer Immunitor, it will be launch a unique M.vaccae and Magnesium dietary supplement in the $18 billion Anxiety and Stress market.
